BCX7353
Published 21st July 2018, updated 26th July 2018
Unassigned
New Medicines
Hereditary angioedema (HAE) type I and II – for prevention of acute attacks
Information
New molecular entity
BioCryst Pharmaceuticals
BioCryst Pharmaceuticals
Development and Regulatory status
Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Category
Small-molecule human plasma kallikrein inhibitor which inhibits isolated human plasma kallikrein activity
HAE affects 1 in 50,000 to 100,000 people of any ethnic group and of either gender. According to the UK population mid-year estimate 2016, there are 65,648,100 people in the UK [1]. ·
Hereditary angioedema (HAE) type I and II – for prevention of acute attacks
Oral